Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell 0.2% during mid-day trading on Friday . The company traded as low as $49.97 and last traded at $50.12. 111,587 shares changed hands during trading, a decline of 68% from the average session volume of 343,386 shares. The stock had previously closed at $50.00.

A number of brokerages recently issued reports on RARE. Jefferies Group LLC reissued a “hold” rating and set a $68.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Stifel Nicolaus reissued a “buy” rating and set a $85.00 price target (down from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Cowen and Company reissued an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, June 29th. Finally, JMP Securities lowered their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.00.

The firm’s market capitalization is $2.12 billion. The company’s 50 day moving average price is $60.55 and its 200 day moving average price is $64.85.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the business earned ($1.46) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in RARE. Sei Investments Co. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $125,000. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 22.6% in the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares in the last quarter. Strs Ohio boosted its position in shares of Ultragenyx Pharmaceutical by 10.7% in the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares in the last quarter. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $213,000. Institutional investors and hedge funds own 96.18% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Stock Price Down 0.2%” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/08/ultragenyx-pharmaceutical-inc-rare-stock-price-down-0-2.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.